Class / Patent application number | Description | Number of patent applications / Date published |
424482000 | Containing solid synthetic polymers | 47 |
20090017118 | COATED TABLETS, THEIR METHODS OF PREPARATION, AND RELATED USES - The present invention relates to a tablet comprising a tabletted core comprising a triglyceride granulate, and an enteric coating surrounding said tabletted core. The invention particularly relates to a tablet wherein the tabletted core contains esterified omega-3 fatty acids such as eicosapentaenoic acid and/or docosahexaenoic acid. | 01-15-2009 |
20090028944 | PHARMACEUTICAL COMPOSITIONS COMPRISING MESALAMINE - Pharmaceutical compositions comprising mesalamine, wherein the compositions are free of a liphophilic matrix, and processes for preparing pharmaceutical compositions comprising mesalamine and being free of a liphophilic matrix. | 01-29-2009 |
20090074867 | ORALLY DISPERSIBLE PHARMACEUTICAL COMPOSITION AND PROCESS FOR THE PREPARATION THEREOF - A process for preparing an orally dispersible solid pharmaceutical form comprises the following steps: a) coating the active ingredient with at least one hydrophilic carboxylate polymer, b) granulating the coated active ingredient obtained in step (a) with at least one lipid compound having a melting point lower than that of the active ingredient, c) mixing the granulate obtained in step (b) with at least one hydrophilic natural polymer having high molecular weight, and d) mixing the granulate obtained in step (c) with ingredients suitable for obtaining an orally dispersible solid pharmaceutical form. An orally dispersible solid pharmaceutical form comprises an active ingredient coated with at least one hydrophilic carboxylate polymer and at least one lipid compound, in which the said coated active ingredient is embedded in a matrix comprising at least one hydrophilic natural polymer having high molecular weight. | 03-19-2009 |
20090175942 | Solid Dosage Form of Olmesartan Medoxomil And Amlodipine - The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof. | 07-09-2009 |
20090186086 | Solid multilayer oral dosage forms - Provided are multilayer compressed oral dosage forms comprising naproxen or a pharmaceutically acceptable salt thereof and sumatriptan or a pharmaceutically acceptable salt thereof. Processes of making and using the oral dosage forms also are described. | 07-23-2009 |
20090186087 | ENTERIC SUSTAINED-RELEASE COATED CORE AND PHARMACEUTICAL DOSAGE FORM AND METHOD FOR MANUFACTURING THE SAME - An enteric sustained-release coated core includes a drug-containing core and a coating film. The coating film includes 20%˜80% by weight of a hydrophobic polymer and 10%˜70% by weight of an enterosoluble material. The dissolution rate of the medical component in the drug-containing core is approximately less than 10% in hydrochloric acid solution of pH 1˜3 after 2 hours. The dissolution of the medical component in the drug-containing core sustains more than 5 hours in phosphate buffer solution of pH 5˜8. | 07-23-2009 |
20090214648 | PHARMACEUTICAL FORMULATIONS COMPRISING IBUPROFEN AND DIPHENHYDRAMINE - A pharmaceutical dosage form comprising diphenhydramine, or a pharmaceutically acceptable salt thereof, and ibuprofen, wherein the dosage form provides both diphenhydramine and ibuprofen in a single monolayer tablet, and processes for preparation of dosage forms. | 08-27-2009 |
20100055181 | CONTROLLED RELEASE DOSAGE FORMS OF ZOLPIDEM - A controlled release dosage forms comprising zolpidem or a salt thereof to release zolpidem to induce rapid onset of sleep, and continue to release zolpidem in a controlled manner to maintain effective plasma concentrations over an extended period of time to improve sleep maintenance. The pharmaceutical controlled-release dosage form of zolpidem or a salt thereof having a dissolution profile when measured in a type I or II dissolution apparatus according to the U.S. Pharmacopoeia in 0.01M hydrochloric acid buffer at 37° C., such that less than 40% is released at the end of 30 minutes. | 03-04-2010 |
20100074952 | TASTED MASKED VETERINARY SOLID COMPOSITIONS - The present invention relates to the supply and production of an animal medicine consisting of a substrate in pellet or tablet form, which is attractive to livestock and domestic animals, in which fine-grained particles of a neutral-tasting, physiologically compatible, solid carrier material are embedded, which is characterised in that said fine-grained particles of carrier material have an average diameter of 0.09 to 0.8 mm and are coated with an active substance from veterinary medicine, and said active substance layer is covered with a protective layer of a physiologically compatible polymer matrix, and to the production of this animal medicine. It also relates to the usage of said double-coated, fine-grained particles of carrier material in the production of a preparation for veterinary medicine. | 03-25-2010 |
20100129446 | SOLID DOSAGE FORMS COMPRISING AN ENTERIC COATING WITH ACCELERATED DRUG RELEASE - The present invention refers to a solid dosage form comprising an inner coating located between a core containing a pharmaceutically active ingredient and an outer enteric coating; wherein said inner coating comprises a partially neutralized anionic polymeric material, and at least a carboxylic acid having 2 to 16 carbon atoms the salts thereof or mixtures of said acid and its salt; wherein said outer coating comprises an anionic polymeric material which is less or not at all neutralized than the material of the inner coating. | 05-27-2010 |
20100233262 | COATED TABLET - A main object of the present invention is to provide a novel coated tablet which contains a drug having a guanidino group and does not suffer an obvious color change even when packed in a one-dose pack together with a drug having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (DMDO) group. The present invention provides a coated tablet characterized in that an uncoated tablet containing a drug having a guanidino group has been coated with a polyvinyl alcohol for film coating which comprises polyvinyl alcohol, acrylic acid, and methyl methacrylate. | 09-16-2010 |
20110002993 | FILM COATED TABLETS CONTAINING DROSPIRENONE AS ACTIVE AGENT AND A METHOD FOR THE PREPARATION THEREOF - The invention relates to drospirenone containing film-coated tablet with improved resistance against the environmental influences, especially against atmospheric humidity. The invention further relates to a method for the preparation film-coated tablet cores whereby applying the active agent to the core may be accomplished with increased safety. | 01-06-2011 |
20110150997 | ELVUCITABINE PHARMACEUTICAL COMPOSITIONS - The invention provides novel pharmaceutical compositions of Elvucitabine. The invention also provides pharmaceutical compositions and oral dosage forms having unique physical-chemical properties. | 06-23-2011 |
20110171303 | DOSAGE FORM CONTAINING (S)-PANTOPRAZOLE AS ACTIVE INGREDIENT - Dosage forms for oral administration of the magnesium salt of (S)-pantoprazole are described. | 07-14-2011 |
20110200672 | COATED TABLET FORMULATION AND METHOD - A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin | 08-18-2011 |
20110274755 | SUPPORTIVE TREATMENT OF LIVER DISEASE - The invention provides a composition and method for treatment of a subject suffering from liver disease comprising the oral administration of a slow release formulation of diltiazem and thiamine. | 11-10-2011 |
20110311628 | PULSATILE RELEASE COMPOSITION OF THERAPEUTIC AGENT - A pulsatile release composition which releases the content rapidly after a predetermined lag time comprising a drug containing a core, coated with a pH sensitive graft copolymer. The coating suppresses the drug release at acidic pH prevalent in the stomach and releases it either immediately or after a lag time in the intestinal region. Combinations of multiple numbers of coated and uncoated units provide a sequential pulsatile release of same or different therapeutic agents. | 12-22-2011 |
20120015033 | ANTISENSE COMPOSITIONS AND METHODS OF MAKING AND USING SAME - The present invention provides pharmaceutical formulations for oral administration of antisense oligonucleotides, such as antisense oligonucleotides against SMAD7. The pharmaceutical formulations can be used to treat Crohn's disease, ulcerative colitis and chronic inflammatory bowel disease. | 01-19-2012 |
20120058186 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR DYSKINESIA - The present invention relates to a stable orally disintegrating coated tablet containing a drug, wherein the tablet is coated with a coating layer containing a water-soluble substance and a polyvinyl alcohol resin of not less than 5% by weight based on the weight of the coating layer, the water-soluble substance dissolving in an amount of 1 g or more in less than 10 mL of water at 20° C., having a hydroxyl group(s) in its molecule, and having a molecular weight of not more than 200 per a unit hydroxyl group. There is provided a stable orally disintegrating coated tablet which does not cause a crack in the coating layer even when the orally disintegrating tablet has been swollen by moisture absorption under high humidity, while ensuring rapid disintegration properties in an oral cavity. In the case of an orally disintegrating tablet containing a light-unstable drug, degradation of the drug can be suppressed by blending a light shading agent in the coating layer. | 03-08-2012 |
20120107400 | SUSTAINED RELEASE COMPOSITION OF THERAPUTIC AGENT - A pH dependent drug delivery system comprising a pH sensitive graft copolymer, a therapeutically active agent and other pharmaceutically acceptable ingredients. More specifically, a composition which is capable of suppressing the drug release in the acidic pH prevalent in the stomach and releasing the drug over an extended period of time at pH prevalent in the intestinal region. | 05-03-2012 |
20120164223 | RAPIDLY DISINTEGRATING, SOLID COATED DOSAGE FORM - Rapidly disintegrating, solid coated dosage form comprising a solid core consisting of at least 60% by weight of an auxiliary mixture, up to 40% by weight of at least one active ingredient, and optionally further auxiliaries, coated with at least one film coating comprising completely or partially hydrolyzed, rapidly water-soluble polyether-vinyl ester graft polymers, methods for the production thereof, and their use. | 06-28-2012 |
20120189697 | COMPOSITIONS OF 1-[2-(2,4-DIMETHYL-PHENYLSULFANYL)-PHENYL]PIPERAZINE - Pharmaceutical compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine and pharmaceutically acceptable acid addition salts thereof adapted so that release does not take place in the stomach is provided. | 07-26-2012 |
20120207834 | ORAL ANTIMICROBIAL PHARMACEUTICAL COMPOSITIONS - The present invention relates to oral pharmaceutical compositions with controlled and/or programmed release containing at least one active ingredient having antimicrobial and/or anti-infectious activity for the treatment of infections of the large intestine, in particular the colon. | 08-16-2012 |
20120219626 | Pharmaceutical Compositions of Sevelamer - The invention relates to a pharmaceutical immediate release tablet comprising a core comprising 70-85 weight percent of sevelamer carbonate, calculated as an anhydrous compound, 10-25 weight percent of lactose monohydrate and, optionally, a water soluble film coat surrounding the to a process of making such tablets, to their use in medicine, and to the use of polyvinyl alcohol-polyethylene glycol graft copolymer for making such coated tablets. | 08-30-2012 |
20120244220 | ATROVASTATIN-CONTAINING COATED PREPARATION - The present invention provides an atorvastatin-containing coated preparation comprising a solid formulation containing atorvastatin, a pharmacologically acceptable atorvastatin salt, or a solvate thereof coated with a coating agent comprising a polyvinyl alcohol copolymer, a method for inhibiting generation of related substances of atorvastatin, a pharmacologically acceptable atorvastatin salt, or a solvate thereof, comprising coating the solid formulation with a coating agent comprising a polyvinyl alcohol copolymer, and a method for stabilizing atorvastatin, a pharmacologically acceptable atorvastatin salt, or a solvate thereof. | 09-27-2012 |
20130004577 | COATED TABLET - A main object of the present invention is to provide a novel coated tablet which contains a drug having a guanidino group and does not suffer an obvious color change even when packed in a one-dose pack together with a drug having a (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl (DMDO) group. The present invention provides a coated tablet characterized in that an uncoated tablet containing a drug having a guanidino group has been coated with a polyvinyl alcohol for film coating which comprises polyvinyl alcohol, acrylic acid, and methyl methacrylate. | 01-03-2013 |
20140017312 | Multi-vitamin and Mineral Nutritional Supplements - The invention provides a nutritional supplement which includes micronutrients to facilitate reduction of cholesterol, and/or reduction of homocystein and/or reduction of low-density lipoprotein-cholesterol (LDL-C) oxidation in humans. In one embodiment the supplement is a multi-vitamin, a mineral supplement which includes at least one component known to reduce cholesterol. The invention further provides a method for tableting one fourth to one half of the daily effective dosage of a phytosterol containing nutritional supplement in a practical sized tablet and a method for reducing blood cholesterol in humans. | 01-16-2014 |
20140056980 | DELAYED RELEASE DRUG FORMULATION - In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base. | 02-27-2014 |
20140093568 | COMBINATION THERAPIES - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention relates to therapies for the treatment of pathological conditions, such as cancer. | 04-03-2014 |
20140248352 | CHEWABLE ENTERIC COATED ASPIRIN TABLETS - The invention relates to a tablet capable of being chewed or disintegrated in the oral cavity, which comprises an enteric coated aspirin active ingredient, and preferably a lightly compressed matrix comprising directly compressible carbohydrate(s) and at least one sweetener. | 09-04-2014 |
20140255486 | Coated Tablet Formulation and Method - A coated tablet formulation is provided which includes a medicament such as the DPP4-inhibitor, saxaglipitin | 09-11-2014 |
20140271859 | MESALAMINE PHARMACEUTICAL COMPOSITION WITH MULTIPLE DOSAGE ELEMENTS FOR REDUCED DELIVERY VARIABILITY - A mesalamine pharmaceutical composition with reduced delivery variability for delivery of mesalamine to the colon that includes multiple dosage elements, and each dosage element includes mesalamine and an enteric coating. The enteric coating of each different dosage element differs so the release point of the mesalamine in the GI tract is varied. In one embodiment, a first dosage element releases about 30% to about 60% by weight of the total mesalamine in the composition after 60 minutes at a pH of about 6.6 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm and a second dosage element releases about 40% to about 70% by weight of the total mesalamine after 60 minutes at a pH of about 7.2 in an aqueous phosphate buffer using a paddle apparatus 2 with a paddle speed of 100 rpm. | 09-18-2014 |
20140271860 | Methods of Treating Colorectal Cancer - Disclosed herein are methods for treating/and or preventing colorectal cancer using a specific inhibitor of SMAD7 expression or function. Also disclosed are pharmaceutical compositions containing an inhibitor of SMAD7 for treating and/or preventing colorectal cancer and manufacture of medicaments containing an inhibitor of SMAD7 to be used in treating and/or preventing colorectal cancer. | 09-18-2014 |
20140308350 | NSAID ADMINISTRATION AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Described herein are methods and systems for treatment and/or prevention of conditions associated with NSAID administration and related compositions. | 10-16-2014 |
20140335181 | DRY COATED TABLET - Provided is a dry coated tablet showing high stability of the active ingredient (proton pump inhibitor, acetylsalicylic acid), which stably and rapidly expresses the pharmacological effect of the active ingredient after administration. A dry coated tablet having an inner core and an outer layer, wherein the inner core is an enteric-coated tablet containing acetylsalicylic acid, and the outer layer contains enteric micro granules containing a proton pump inhibitor. | 11-13-2014 |
20140335182 | AQUEOUS POLYMER DISPERSION BASED ON N,N-DIETHYLAMINOETHYL METHACRYLATE, ITS PREPARATION AND USE - The present invention relates to a process for preparing an aqueous polymer dispersion by free-radical emulsion polymerization of a monomer mixture which comprises N,N-diethylaminoethyl methacrylate, to the polymer dispersion obtainable by this process, and to the use thereof. | 11-13-2014 |
20140341994 | FORMULATIONS AND PHARMACOKINETICS OF DEUTERATED BENZOQUINOLINE INHIBITORS OF VESICULAR MONOAMINE TRANSPORTER 2 - The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders. | 11-20-2014 |
20140377353 | PHARMACEUTICAL PRODUCT TO INDUCE ENDOGENOUS EXACERBATED RELEASE OF GUT HORMONES PYY AND GLP1 WITH THERAPEUTIC EFFECT ON OBESITY AND TYPE 2 DIABETES MELLITUS - The present invention concerns a pharmaceutical product to induce endogenous exacerbated release of gut hormones, pyy and glp1, with therapeutic effect on obesity and type 2 diabetes mellitus. In tablets form, suitable dosage forms such as pills capable of disintegration from a certain range of Ph or specific Ph range between 6.0 and 7.0, so that the undigested or partially hydrolyzed content is released in the distal jejunum and preferably in the ileum/proximal colon. And by contact with macro-nutrient molecules, or their hydrolyzed fragments, such cells suffer intense amplified stimulus and secrete the said hormones, released at rates that are therapeutics for obesity of any degree and also for type II diabetes; mimicking that produced and performed in bariatric and metabolic surgeries by a noninvasive method. | 12-25-2014 |
20150024049 | CONTROLLED RELEASE PHARMACEUTICAL COMPOSITIONS COMPRISING A FUMARIC ACID ESTER - The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side effects. | 01-22-2015 |
20150064252 | SOLID DISPERSION FORMULATION OF AN ANTIVIRAL COMPOUND - Disclosed are solid dispersions comprising a compound having the formula: | 03-05-2015 |
20150064253 | COMBINATION FORMULATION OF TWO ANTIVIRAL COMPOUNDS - Disclosed are pharmaceutical compositions comprising Compound I, having the formula: | 03-05-2015 |
20150110873 | ENTERIC TABLET - The present invention relates to an enteric tablet with improved bioavailability, which is rapidly disintegrated after reaching the intestine to allow dissolution of the active ingredient, and which characteristically reduces the amount of talc to be used and is free of an alkali component. | 04-23-2015 |
20150132382 | COMPOSITIONS AND METHODS OF TREATMENT COMPRISING FOSFOMYCIN DISODIUM - The present invention provides compositions comprising fosfomycin or a pharmaceutically acceptable salt, solvate or prodrug thereof (e.g., fosfomycin disodium) alone or in combination with an antibacterial agent. The present invention provides methods of treating bacterial infections, which include administering an effective amount of fosfomycin or a pharmaceutically acceptable salt, solvate or a prodrug thereof (e.g., fosfomycin disodium) alone or in combination with an antibacterial agent. | 05-14-2015 |
20160030473 | DUAL USE ORAL PHARMACEUTICAL COMPOSITION TABLETS OF SULFATE SALTS AND METHODS OF USE THEREOF - The present invention is generally directed to an oral pharmaceutical tablet composition comprising a sulfate salt, for example, sodium sulfate, wherein the composition is capable of administration by direct oral ingestion and by disintegration in water prior to oral ingestion. The present invention is further directed to use of such oral pharmaceutical tablet formulations to induce laxation or to treat or prevent constipation. | 02-04-2016 |
20160045441 | Pharmaceutical Compositions Comprising Everolimus - The invention relates to a pharmaceutical formulation comprising 40-O-(2-hydroxy)ethyl-rapamycin in a high drug load part and an immediate release part. In addition, the invention relates to a formulation comprising 40-O-(2-hydroxyethyl-rapamycin in a first layer and a surfactant in a layer beneath the first layer. The pharmaceutical composition is particularly suitable for use as a medicament. | 02-18-2016 |
20160129008 | Solid Dosage Form of Olmesartan Medoxomil and Amlodipine - The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof. | 05-12-2016 |
20160193182 | COATING COMPOSITION | 07-07-2016 |